Accelerate your clinical trial with expertise in breast cancer drug development

ppd

Advancements in breast cancer screening, early detection, and improvements in both early breast cancer and metastatic disease treatments have resulted in decreasing mortality rates since the 1970s. However, breast cancer remains the most frequently diagnosed malignancy globally — accounting for more than 2 million cases each year — and is the leading cause of cancer deaths in women. This demands urgent attention and innovative solutions through research and clinical trials.

Despite demonstrated progress, challenges remain. Continued research is critical to develop more effective and targeted therapies. The PPD™ clinical research business of Thermo Fisher Scientific is experienced in accelerating development — combining global expertise, operational excellence, and a robust network of clinical trial sites to support recruitment, retention, and trial success

More than 90% of breast cancers are local or regional when first detected and fewer than 10% of cases are diagnosed after distant metastases have already developed.

Regardless of the type of diagnosis, breast cancer presents several challenges for patients and their caregivers across many different domains, including medical, psychological, and societal aspects. Some of the key challenges include:.



Some key challenges include:

Similarly, researching and developing new treatments for breast cancer involves complex, varied challenges that demand robust, innovative and patient-centered strategies.

Addressing these challenges requires a multifaceted approach involving advancements in medical research, improvements in health care systems, and support for patients and their families.

We have contributed to the approvals of 12 breast cancer treatments over the past 10 years across the U.S, Canada, Europe and China.

In the past five years, our expert breast cancer team has supported close to 50 breast cancer trials, ranging from Phase I to Phase IV. Our experience spans all key morphological subtypes, including HR+/ER+, HER2-, HER2+ and TNBC. Sponsors have turned to us to support trials exploring key gene mutation and biomarker targets such as PIK3CA, ESR1, BRCA1/2, PDL1, FSH, GPNMB, KRAS, EGFR, PSA.

When you partner with us on your breast cancer clinical trials, you gain our:

- Ability to beat enrollment timelines through a unified team approach that emphasizes timely interventions to support high enrolling and non-enrolling sites
- Data-driven process for site list development and inclusion of less research saturated territories to mitigate competition for patients
- Accelerated site startup and increased enrollment using our strategic site collaboration network
- Timely data analysis by close cross-departmental collaboration
- Reduced global site activation timelines using innovative site feasibility and activation strategies

Unmatched breast cancer knowledge and experience

Breast cancer research is complex and requires a deep understanding of the disease to unlock clinical development success. Our understanding of breast cancer has shifted from that of a single disease, through common clinical sub-types to our current understanding of multiple rare heterogenous diseases within those subtypes. Treatment for breast cancer is transitioning from targeted treatment toward a 'less is more' treatment approach.

Oncology and breast cancer-specific expertise powers our medical and operational organization, giving us the ability to leverage this broad experience base and develop the optimal strategies for your study's success.

6,900+ global oncology experienced staff

2,650+ global breast cancer experienced staff

Easing enrollment and increasing retention with patient-centric services

Clinical trials can be burdensome for patients and their caregivers. Our host of supportive concierge services reduces the burden for both sites and patients and **makes it easier for patients to participate in trials** by offering:

- **Telemedicine & Home Health Care Services**
- **Digital & Decentralized Protocols**
- **Transportation Coordination & Verification**
- **eCOA/ePRO**
- **Flexible Reimbursement Options**
- **Wearable & Mobile Pagers**

The advantages of decentralizing clinical studies includes:

- Reduction in recruitment timelines
- Improved patient retention
- Patient readiness
- Improved patient diversity

These services **produce timely and high-quality data** for our clients while saving patients' time and cost. Our patient-centric approach has led to a **patient retention rate of more than 90%** over five years for a recent long-term follow-up trial.

Continuous engagement and support from our Patient First Digital solutions Center of Excellence

Our locate, match and enroll framework enables us to accelerate enrollment, drive retention and improve data quality. Significant investments in breast cancer allow us to bring new and innovative solutions to recruit patients.

Locate

- Creative solutions that include study branding and websites
- Collaborations with online patient communities and patient advocacy groups
- Use AI to access patients' medical records and identify patients that meet inclusion/exclusion criteria

Match

- Apply secondary solutions to increase the quality of patients and the probability of success while decreasing site burden
- SMART screening through AI-enabled patient workflow, with real time health care validation

Enroll

- Enroll eligible patients to sites and reduce patient and site burden
- Tailor retention strategies including digital solutions and patient navigators to support patients and families through a study